Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

mylan institutional inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 200 mg - carbamazepine tablets usp and carbamazepine tablets usp (chewable) are indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine tablets usp and carbamazepine tablets usp (chewable) as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine tablets usp and carbamazepine tablets usp (chewable) (see precautions , general ). carbamazepine tablets usp and ca

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 200 mg - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. 2. generalized tonic-clonic seizures (grand mal). 3. mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, h

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

remedyrepack inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 200 mg - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. likewise, on theoretical grounds its use with monoamine oxidase (mao) inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - carbatrol is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:      - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvements than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general ). carbatrol is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hyper

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 200 mg - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marro

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.625 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to prempro/premphase - known liver dysfunction or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing women has been shown t

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

wyeth pharmaceutical division of wyeth holdings llc - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen 2.2 ug in 0.5 ml - in children 6 weeks through 5 years of age (prior to the 6th birthday), prevnar 13® is indicated for: in children 6 years through 17 years of age (prior to the 18th birthday), prevnar 13 is indicated for: risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on prevnar 13 administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study has been performed in female rabbits administered prevnar 13 prior to mating and during gestation. each dose was approximately 20 times the human dose. this study revealed no evidence of harm to the fetus due to prevnar 13 (see 8.1 data). data animal in a developmental toxicity study, female rabbits were administered prevnar 13 by intramuscular injection twice prior to mating (17 days an

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

remedyrepack inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - tegretol is indicated for use as an anticonvulsant drug. evidence supporting efficacy of tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by tegretol (see precautions, general). tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. tegretol should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug,

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

morton grove pharmaceuticals, inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg in 5 ml - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hype

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen 2.2 ug in 0.5 ml - in children 6 weeks through 5 years of age (prior to the 6th birthday), prevnar 13® is indicated for: in children 6 years through 17 years of age (prior to the 18th birthday), prevnar 13 is indicated for: risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on prevnar 13 administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study has been performed in female rabbits administered prevnar 13 prior to mating and during gestation. each dose was approximately 20 times the human dose. this study revealed no evidence of harm to the fetus due to prevnar 13 (see 8.1 data). data animal in a developmental toxicity study, female rabbits were administered prevnar 13 by intramuscular injection twice prior to mating (17 days an